{"version":"1.0","provider_name":"Breakthrough T1D","provider_url":"https:\/\/breakthrought1d.eu\/nl","author_name":"ylt-admin","author_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/","title":"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hn1Wb09Z2T\"><a href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\">Mesochymale stamcellen triggeren geen afweer<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/embed\/#?secret=hn1Wb09Z2T\" width=\"600\" height=\"338\" title=\"&#8220;Mesochymale stamcellen triggeren geen afweer&#8221; &#8212; Breakthrough T1D\" data-secret=\"hn1Wb09Z2T\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/breakthrought1d.eu\/nl\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Een jaar geleden startte Osiris Therapeutics met Breakthrough T1D een fase 2 klinische trial met Prochymal, een intraveneus toegediend middel dat mesochymale stamcellen (MSC\u2019s) bevat. De stamcellen waren afkomsitg van niet verwante donoren en er werd geen immunosuppressie toegepast bij de ontvangers. Desondanks werd er geen reactie van het afweer systeem geconstateerd. Hoewel de progressie [&hellip;]"}